Tesamorelin is not a belly-fat shortcut
No. Tesamorelin has a real prescription context for reducing excess abdominal fat in adults with HIV-associated lipodystrophy, but that does not make it a generic fat-loss, physique, or anti-aging shortcut.
No. Tesamorelin has a real prescription context for reducing excess abdominal fat in adults with HIV-associated lipodystrophy, but that does not make it a generic fat-loss, physique, or anti-aging shortcut.
FDA EGRIFTA WR/SV labeling keeps tesamorelin in a narrow HIV-associated lipodystrophy context, says it is not indicated for weight-loss management, says long-term cardiovascular safety has not been established, and says WR and SV are not substitutable. Randomized trials and a meta-analysis support visceral-adipose-tissue changes in adults with HIV-associated lipodystrophy, not casual spot-reduction, body recomposition, longevity, or wellness-clinic peptide claims.
What to do instead
Do not borrow tesamorelin evidence from HIV-associated lipodystrophy care for ordinary belly-fat, anti-aging, or physique marketing. Visceral-fat treatment, HIV care, obesity medication decisions, hormone-axis concerns, malignancy history, diabetes or glucose intolerance, pregnancy, medication interactions, formulation identity, adverse-event monitoring, and tested sport all belong in clinician or anti-doping context.
“Tesamorelin is a simple peptide shortcut for belly fat, body recomposition, and anti-aging.”
At a glance
- Status: published
- Topic: Supplements
- Author: No Lies Lifting Editorial